Pinar Akokay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pinar Akokay has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Çağatay Bilen
Aydın Adnan Menderes University, Faculty of Medicine, Department of Cardiovascular Surgery, Aydın, Türkiye
7 shared publications - Tugra Gencpinar
Department of Cardiovascular Surgery, Dokuz Eylül University Faculty of Medicine, Izmir, Türkiye
6 shared publications - Mustafa Barış Kemahlı
Acıbadem Kent Hospital, İzmir, Turkey
5 shared publications - Serdar Bayrak
Department of Cardiovascular Surgery, Dokuz Eylül University Faculty of Medicine, Izmir, Türkiye
5 shared publications Cenk Erdal
Department of Cardiovascular Surgery, Dokuz Eylül University Faculty of Medicine, Izmir, Türkiye
2 shared publications- Ferhat Dindas
Usak University Training and Research Hospital, Turquia
2 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 35 (1) , 7-13
Dapagliflozin attenuates histopathological alterations in a rat model of abdominal aortic aneurysm
Aim: Abdominal aortic aneurysm is a progressive enlargement of the abdominal aorta associated with high mortality risk. Despite advances in surgical and endovascular treatments, no pharmacological therapy has been established to prevent aneurysm growth. Dapagliflozin, a sodium–glucose cotransporter-2 inhibitor, has demonstrated cardiovascular benefits beyond glycemic control. The aim of this study was to investigate the effects of dapagliflozin in a calcium phosphate–induced rat model of abdominal aortic aneurysm.Material and Methods: Twenty male Wistar albino rats were randomly divided into three groups: sham operated rats (Sham, n=6), rats with abdominal aortic aneurysm induced by calcium phosphate (AAA, n=7), and rats with aneurysm treated with dapagliflozin (Dapagliflozin group, n=7). Aneurysm formation was induced by periaortic application of calcium phosphate. The Dapagliflozin group received daily oral dapagliflozin at a dose of 1 mg/kg for 28 days. Morphometric parameters including lumen area, lumen plus intima area, and lumen plus intima plus media area were evaluated using hematoxylin–eosin staining. Elastin degradation was assessed with Van Gieson staining, vascular calcification with Alizarin Red staining, and apoptosis with immunohistochemical detection of Caspase-3 and Caspase-9. Statistical analyses were performed using Student’s t-test and Mann–Whitney U test, with a significance threshold of p<0.05.Results: Morphometric parameters were significantly increased in the AAA group compared with the Sham group (all p<0.001). These parameters were reduced in the Dapagliflozin group compared with the AAA group (all p<0.001). Elastin degradation and calcium deposition were higher in the AAA group compared with Sham (p=0.001 and p=0.002) and decreased with dapagliflozin treatment (p=0.001 and p=0.012). Caspase-3 and Caspase-9 expression was elevated in the AAA group (p=0.002 and p=0.003) and decreased in the Dapagliflozin group, although the reduction in Caspase-9 did not reach statistical significance (p=0.068).Conclusion: Dapagliflozin reduced aortic dilatation, elastin degradation, vascular calcification, and Caspase-3–mediated apoptosis in a calcium phosphate–induced rat model of abdominal aortic aneurysm. These findings suggest that dapagliflozin exerts protective effects on vascular integrity beyond glucose regulation and may represent a potential medical therapy for abdominal aortic aneurysm.
- 12 January 2026
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 35 (1) , 7-13
Open AccessDapagliflozin attenuates histopathological alterations in a rat model of abdominal aortic aneurysm
Aim: Abdominal aortic aneurysm is a progressive enlargement of the abdominal aorta associated with high mortality risk. Despite advances in surgical and endovascular treatments, no pharmacological therapy has been established to prevent aneurysm growth. Dapagliflozin, a sodium–glucose cotransporter-2 inhibitor, has demonstrated cardiovascular benefits beyond glycemic control. The aim of this study was to investigate the effects of dapagliflozin in a calcium phosphate–induced rat model of abdominal aortic aneurysm.Material and Methods: Twenty male Wistar albino rats were randomly divided into three groups: sham operated rats (Sham, n=6), rats with abdominal aortic aneurysm induced by calcium phosphate (AAA, n=7), and rats with aneurysm treated with dapagliflozin (Dapagliflozin group, n=7). Aneurysm formation was induced by periaortic application of calcium phosphate. The Dapagliflozin group received daily oral dapagliflozin at a dose of 1 mg/kg for 28 days. Morphometric parameters including lumen area, lumen plus intima area, and lumen plus intima plus media area were evaluated using hematoxylin–eosin staining. Elastin degradation was assessed with Van Gieson staining, vascular calcification with Alizarin Red staining, and apoptosis with immunohistochemical detection of Caspase-3 and Caspase-9. Statistical analyses were performed using Student’s t-test and Mann–Whitney U test, with a significance threshold of p<0.05.Results: Morphometric parameters were significantly increased in the AAA group compared with the Sham group (all p<0.001). These parameters were reduced in the Dapagliflozin group compared with the AAA group (all p<0.001). Elastin degradation and calcium deposition were higher in the AAA group compared with Sham (p=0.001 and p=0.002) and decreased with dapagliflozin treatment (p=0.001 and p=0.012). Caspase-3 and Caspase-9 expression was elevated in the AAA group (p=0.002 and p=0.003) and decreased in the Dapagliflozin group, although the reduction in Caspase-9 did not reach statistical significance (p=0.068).Conclusion: Dapagliflozin reduced aortic dilatation, elastin degradation, vascular calcification, and Caspase-3–mediated apoptosis in a calcium phosphate–induced rat model of abdominal aortic aneurysm. These findings suggest that dapagliflozin exerts protective effects on vascular integrity beyond glucose regulation and may represent a potential medical therapy for abdominal aortic aneurysm.
- Open Access
- 1 April 2025
- Published by Wiley in Journal of Experimental Orthopaedics
- Vol. 12 (2) , e70267
Comparative effects of hip capsule repair and cam lesion excision on capsulotomy healing: An in vivo biomechanical and histological analysis
Purpose: This study evaluates the effects of hip capsule repair and cam lesion excision on capsular healing by assessing biomechanical strength and histological integrity in an in vivo rabbit model.Methods: An in vivo rabbit model with 80 rabbits was used, where capsulotomy was performed on the right hip of each subject. The rabbits were assigned into four groups: Group 1 (capsulotomy without repair), Group 2 (capsulotomy with capsule repair), Group 3 (capsulotomy + cam resection without repair), Group 4 (capsulotomy + cam resection + capsule repair). Each group was stratified into 4‐week and 8‐week follow‐up subgroups. Biomechanical testing assessed maximum tensile strength, while histological evaluation included semiquantitative grading of collagen arrangement, inflammatory response, osteogenesis, and angiogenesis.Results: Histological analysis revealed superior healing in the capsule repair + cam resection group (Group 4) compared to the unrepaired capsulotomy group (Group 1) (p = 0.01). Biomechanical testing demonstrated that capsule repair (Group 2) improved strength over unrepaired capsulotomy (135.2 N vs. 111.9 N, p = 0.03). Cam resection alone (Group 3) resulted in significantly higher strength than unrepaired capsulotomy (163.2 N vs. 111.9 N, p = 0.01). The combination of cam resection and capsule repair (Group 4) demonstrated superior strength, outperforming capsule repair alone (176 N vs. 135.2 N, p = 0.01). At 8 weeks, the capsule repair + cam resection group (Group 4a) showed significantly enhanced biomechanical strength compared to the unrepaired capsulotomy group (Group 1a) (181.6 N vs. 120.9 N, p = 0.001) and capsule repair alone (Group 2a) (181.6 N vs. 125.8 N, p = 0.01).Conclusion: Our findings indicate that cam resection, particularly when combined with capsule repair, significantly improves biomechanical strength and enhances the healing process of the capsule. These findings offer practical guidance for optimising surgical strategies to enhance patient outcomes and long‐term joint function.Level of Evidence: Level III, experimental therapeutic study (prospective and controlled).
- 1 April 2025
- Published by Wiley in Journal of Experimental Orthopaedics
- Vol. 12 (2) , e70267
Open AccessComparative effects of hip capsule repair and cam lesion excision on capsulotomy healing: An in vivo biomechanical and histological analysis
Purpose: This study evaluates the effects of hip capsule repair and cam lesion excision on capsular healing by assessing biomechanical strength and histological integrity in an in vivo rabbit model.Methods: An in vivo rabbit model with 80 rabbits was used, where capsulotomy was performed on the right hip of each subject. The rabbits were assigned into four groups: Group 1 (capsulotomy without repair), Group 2 (capsulotomy with capsule repair), Group 3 (capsulotomy + cam resection without repair), Group 4 (capsulotomy + cam resection + capsule repair). Each group was stratified into 4‐week and 8‐week follow‐up subgroups. Biomechanical testing assessed maximum tensile strength, while histological evaluation included semiquantitative grading of collagen arrangement, inflammatory response, osteogenesis, and angiogenesis.Results: Histological analysis revealed superior healing in the capsule repair + cam resection group (Group 4) compared to the unrepaired capsulotomy group (Group 1) (p = 0.01). Biomechanical testing demonstrated that capsule repair (Group 2) improved strength over unrepaired capsulotomy (135.2 N vs. 111.9 N, p = 0.03). Cam resection alone (Group 3) resulted in significantly higher strength than unrepaired capsulotomy (163.2 N vs. 111.9 N, p = 0.01). The combination of cam resection and capsule repair (Group 4) demonstrated superior strength, outperforming capsule repair alone (176 N vs. 135.2 N, p = 0.01). At 8 weeks, the capsule repair + cam resection group (Group 4a) showed significantly enhanced biomechanical strength compared to the unrepaired capsulotomy group (Group 1a) (181.6 N vs. 120.9 N, p = 0.001) and capsule repair alone (Group 2a) (181.6 N vs. 125.8 N, p = 0.01).Conclusion: Our findings indicate that cam resection, particularly when combined with capsule repair, significantly improves biomechanical strength and enhances the healing process of the capsule. These findings offer practical guidance for optimising surgical strategies to enhance patient outcomes and long‐term joint function.Level of Evidence: Level III, experimental therapeutic study (prospective and controlled).
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (12) , e20251136
Enoxaparin preserves cellular morphology and modulates mitophagy-associated Parkin–LC3 in acute ischemic rat myocardium
SUMMARY OBJECTIVE: Despite the longstanding clinical use of low-molecular-weight heparins and their well-characterized mechanisms of action, their effects on mitophagy pathways in acute myocardial ischemia remain incompletely delineated. The aim of this study was to investigate the enoxaparin effect on cardiomyocyte morphology and the immunopositivity of mitophagy-associated Parkin–LC3 proteins in a rat model of acute myocardial ischemia. METHODS: Female Wistar albino rats (median weight: 400 g, minimum: 375 g-maximum: 415 g) were divided into sham (n=7), control (n=7), and treatment (n=7) groups. The control group received subcutaneous 0.9% saline (0.2 mL/kg) twice daily for 28 days, followed by the induction of myocardial ischemia. The treatment group was administered subcutaneous enoxaparin sodium (1 mg/kg) twice daily for the same duration before undergoing myocardial ischemia. Myocardial ischemia was induced by occluding the proximal left anterior descending coronary artery using a 6-0 polypropylene suture for 10 min. Morphometric calculations of cardiomyocytes (cell length and diameter) were performed using light microscopy. Immunohistochemical analysis was performed using anti-Parkin and anti-LC3 antibodies, and immunopositive cells were counted. RESULTS: Statistically significant differences were found between the groups (p<0.001). Post-hoc analysis revealed significant differences between the control and treatment groups based on cell length, cell diameter, Parkin, and LC3 values (p<0.001, p=0.001, p<0.001, and p=0.001, respectively). CONCLUSION: This study demonstrated that enoxaparin preserved cardiomyocyte morphology and reduced the number of Parkin–LC3 immunopositive cells in a model of induced acute ischemic injury in rat myocardium.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (12) , e20251136
Open AccessEnoxaparin preserves cellular morphology and modulates mitophagy-associated Parkin–LC3 in acute ischemic rat myocardium
SUMMARY OBJECTIVE: Despite the longstanding clinical use of low-molecular-weight heparins and their well-characterized mechanisms of action, their effects on mitophagy pathways in acute myocardial ischemia remain incompletely delineated. The aim of this study was to investigate the enoxaparin effect on cardiomyocyte morphology and the immunopositivity of mitophagy-associated Parkin–LC3 proteins in a rat model of acute myocardial ischemia. METHODS: Female Wistar albino rats (median weight: 400 g, minimum: 375 g-maximum: 415 g) were divided into sham (n=7), control (n=7), and treatment (n=7) groups. The control group received subcutaneous 0.9% saline (0.2 mL/kg) twice daily for 28 days, followed by the induction of myocardial ischemia. The treatment group was administered subcutaneous enoxaparin sodium (1 mg/kg) twice daily for the same duration before undergoing myocardial ischemia. Myocardial ischemia was induced by occluding the proximal left anterior descending coronary artery using a 6-0 polypropylene suture for 10 min. Morphometric calculations of cardiomyocytes (cell length and diameter) were performed using light microscopy. Immunohistochemical analysis was performed using anti-Parkin and anti-LC3 antibodies, and immunopositive cells were counted. RESULTS: Statistically significant differences were found between the groups (p<0.001). Post-hoc analysis revealed significant differences between the control and treatment groups based on cell length, cell diameter, Parkin, and LC3 values (p<0.001, p=0.001, p<0.001, and p=0.001, respectively). CONCLUSION: This study demonstrated that enoxaparin preserved cardiomyocyte morphology and reduced the number of Parkin–LC3 immunopositive cells in a model of induced acute ischemic injury in rat myocardium.
- Open Access
- 1 October 2024
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 32 (4) , 378-386
The effect of edoxaban on apoptosis in an abdominal aortic aneurysm model in rats
Background: This study aimed to evaluate the effects of edoxaban, which is used in venous thrombosis, systemic embolism, and stroke, on an aortic aneurysm model and to demonstrate the pharmacokinetic and molecular effects of edoxaban through the induction of apoptosis. Methods: In this double-blind experimental study, 21 Wistar albino male rats (mean weight: 290 g; range, 280 to 300 g) were divided into three groups: the sham group (n=7), the abdominal aortic aneurysm (AAA) group (n=7), and the AAA-edoxaban group (n=7). Edoxaban 10 mg/kg was given to the AAA-edoxaban group by oral gavage daily for 30 days. At the end of 30 days, the aneurysmal aorta was surgically removed and histologically examined. The abdominal aorta was surgically exposed and wrapped with a calcium chloride (0.5 mol/L) sponge for 10 min. Results: Immunohistochemically, aortic sections were marked with caspase-3 and caspase-9 antibodies. It was observed that the pathways that trigger apoptosis (caspase-3 and caspase-9; p< 0.004 and p< 0.005, respectively) were significantly reduced in the AAA-edoxaban group compared to the AAA group. In the AAA-edoxaban group, it was observed that the expansion in aortic diameter and the deterioration in the elastic fibril structure in the aortic aneurysm were decreased as a result of edoxaban treatment. Edoxaban treatment was observed to reduce cell death in both the tunica intima and tunica media. Conclusion: This study provided strong evidence of the protective effect of edoxaban on aortic aneurysm-related vascular damage by reducing apoptosis and mitophagy.
- 1 October 2024
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 32 (4) , 378-386
Open AccessThe effect of edoxaban on apoptosis in an abdominal aortic aneurysm model in rats
Background: This study aimed to evaluate the effects of edoxaban, which is used in venous thrombosis, systemic embolism, and stroke, on an aortic aneurysm model and to demonstrate the pharmacokinetic and molecular effects of edoxaban through the induction of apoptosis. Methods: In this double-blind experimental study, 21 Wistar albino male rats (mean weight: 290 g; range, 280 to 300 g) were divided into three groups: the sham group (n=7), the abdominal aortic aneurysm (AAA) group (n=7), and the AAA-edoxaban group (n=7). Edoxaban 10 mg/kg was given to the AAA-edoxaban group by oral gavage daily for 30 days. At the end of 30 days, the aneurysmal aorta was surgically removed and histologically examined. The abdominal aorta was surgically exposed and wrapped with a calcium chloride (0.5 mol/L) sponge for 10 min. Results: Immunohistochemically, aortic sections were marked with caspase-3 and caspase-9 antibodies. It was observed that the pathways that trigger apoptosis (caspase-3 and caspase-9; p< 0.004 and p< 0.005, respectively) were significantly reduced in the AAA-edoxaban group compared to the AAA group. In the AAA-edoxaban group, it was observed that the expansion in aortic diameter and the deterioration in the elastic fibril structure in the aortic aneurysm were decreased as a result of edoxaban treatment. Edoxaban treatment was observed to reduce cell death in both the tunica intima and tunica media. Conclusion: This study provided strong evidence of the protective effect of edoxaban on aortic aneurysm-related vascular damage by reducing apoptosis and mitophagy.
- Open Access
- 18 June 2024
- Published by Wiley in Food Science & Nutrition
- Vol. 12 (9) , 6461-6471
Fig seed oil improves intestinal damage caused by 5‐FU‐induced mucositis in rats
Intestinal mucositis poses a significant concern associated with cancer therapy. This study aims to investigate the protective and/or healing effect of fig seed oil (FSO) on 5‐fluorouracil (5‐FU)‐induced intestinal mucositis by targeting inflammatory markers and histologic changes in rats. Albino Wistar adult rats were randomly divided into four groups, including three male and three female animals. All the animals in the four groups had a normal standard diet and water throughout the experimental period, which lasted up to 11 days. Rats were administered FSO 0.6 mL (mucositis FSO group) and FSO 0.2 mL (mucositis FSO‐R group) daily throughout the experiment. These two groups and one additional group (mucositis group) were given an intraperitoneal injection of 5‐FU (300 mg/kg) on Day 5 of the experiment. In contrast, the fourth group (Control group) was given an intraperitoneal saline injection on Day 5 of the experiment. FSO treatment ameliorated 5‐FU‐induced intestinal mucositis. On immunohistologic examination, FSO suppressed significantly the activation of NF‐κB and expression of IL‐β and TNF‐α of the harvested intestinal tissue. The reduced dose FSO (mucositis FSO‐R) was as effective as the full dose (mucositis FSO) in suppressing IL‐β and TNF‐α production, but was not as effective as the full dose in suppressing NF‐κB. On light microscopy, FSO attenuated significantly 5‐FU‐induced anomalies, such as the reduction of intestinal villus length and Goblet cell count. The reduced dose FSO (mucositis FSO‐R) was as effective as the full dose (mucositis FSO) in restoring villus length, but was not as effective as the full dose in restoring Goblet cell count. The findings of the study suggest that FSO inhibits 5‐FU‐induced intestinal mucositis via modulation of mucosal inflammation.
- 18 June 2024
- Published by Wiley in Food Science & Nutrition
- Vol. 12 (9) , 6461-6471
Open AccessFig seed oil improves intestinal damage caused by 5‐FU‐induced mucositis in rats
Intestinal mucositis poses a significant concern associated with cancer therapy. This study aims to investigate the protective and/or healing effect of fig seed oil (FSO) on 5‐fluorouracil (5‐FU)‐induced intestinal mucositis by targeting inflammatory markers and histologic changes in rats. Albino Wistar adult rats were randomly divided into four groups, including three male and three female animals. All the animals in the four groups had a normal standard diet and water throughout the experimental period, which lasted up to 11 days. Rats were administered FSO 0.6 mL (mucositis FSO group) and FSO 0.2 mL (mucositis FSO‐R group) daily throughout the experiment. These two groups and one additional group (mucositis group) were given an intraperitoneal injection of 5‐FU (300 mg/kg) on Day 5 of the experiment. In contrast, the fourth group (Control group) was given an intraperitoneal saline injection on Day 5 of the experiment. FSO treatment ameliorated 5‐FU‐induced intestinal mucositis. On immunohistologic examination, FSO suppressed significantly the activation of NF‐κB and expression of IL‐β and TNF‐α of the harvested intestinal tissue. The reduced dose FSO (mucositis FSO‐R) was as effective as the full dose (mucositis FSO) in suppressing IL‐β and TNF‐α production, but was not as effective as the full dose in suppressing NF‐κB. On light microscopy, FSO attenuated significantly 5‐FU‐induced anomalies, such as the reduction of intestinal villus length and Goblet cell count. The reduced dose FSO (mucositis FSO‐R) was as effective as the full dose (mucositis FSO) in restoring villus length, but was not as effective as the full dose in restoring Goblet cell count. The findings of the study suggest that FSO inhibits 5‐FU‐induced intestinal mucositis via modulation of mucosal inflammation.
- Open Access
- 1 July 2023
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 31 (3) , 301-308
Effects of rivaroxaban on myocardial mitophagy in the rat heart
Background: This study aims to demonstrate the efficacy of rivaroxaban’s pharmacokinetic effects on myocardial mitophagy in rats by inducing apoptosis. Methods: In this double-blind experiment, Wistar albino male rats were randomly divided into three groups for an experimental ischemia model: the sham group (Group 1; n=7), the control group (Group 2; n=7), and the drug group (Group 3; n=7). Rivaroxaban was perorally administered with gavage at 2 mg/ kg/day for 28 days in Group 3. The heart was surgically exposed, and ischemia was achieved by compressing the vessel around the proximal part of the left anterior descending coronary artery for 10 min. The heart tissue was then transected, removed, and morphologically and immunohistochemically examined under a light microscope. Results: Heart sections were immunohistochemically marked with caspase 3, caspase 9, APAF1, and Bcl-2 antibodies. Group 1 was compared to the rivaroxaban-treated group, and the pathways inducing apoptosis was increased (caspase 3, caspase 9, APAF1; p Conclusion: The present study provides an evidence that the mitophagy response is less in rivaroxaban-treated rats, showing the protective effect of rivaroxaban against acute ischemia. Rivaroxaban-treated rats may have reduced cell death in cardiomyocytes during myocardial infarction and thus have reduced damage to the heart tissue caused by myocardial infarction.
- 1 July 2023
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 31 (3) , 301-308
Open AccessEffects of rivaroxaban on myocardial mitophagy in the rat heart
Background: This study aims to demonstrate the efficacy of rivaroxaban’s pharmacokinetic effects on myocardial mitophagy in rats by inducing apoptosis. Methods: In this double-blind experiment, Wistar albino male rats were randomly divided into three groups for an experimental ischemia model: the sham group (Group 1; n=7), the control group (Group 2; n=7), and the drug group (Group 3; n=7). Rivaroxaban was perorally administered with gavage at 2 mg/ kg/day for 28 days in Group 3. The heart was surgically exposed, and ischemia was achieved by compressing the vessel around the proximal part of the left anterior descending coronary artery for 10 min. The heart tissue was then transected, removed, and morphologically and immunohistochemically examined under a light microscope. Results: Heart sections were immunohistochemically marked with caspase 3, caspase 9, APAF1, and Bcl-2 antibodies. Group 1 was compared to the rivaroxaban-treated group, and the pathways inducing apoptosis was increased (caspase 3, caspase 9, APAF1; p Conclusion: The present study provides an evidence that the mitophagy response is less in rivaroxaban-treated rats, showing the protective effect of rivaroxaban against acute ischemia. Rivaroxaban-treated rats may have reduced cell death in cardiomyocytes during myocardial infarction and thus have reduced damage to the heart tissue caused by myocardial infarction.
- Open Access
- 25 October 2022
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 31 (3) , 148-156
Effects of rivaroxaban and apixaban on intimal hyperplasia in rabbits
Aim: Intimal hyperplasia causes vascular occlusion and its optimal treatment is unknown. In this study, we evaluated the effectiveness of Apixaban and Rivaroxaban treatment for preventing intimal hyperplasia in rabbits. Material and Methods: The rabbits (n = 15) were randomly divided into three groups. Reanastomoses are applied to the carotid artery. All groups received 100 U/kg heparin sodium during the operation period. Group A (n = 5) as a control group had no medication. Group B (n = 5) was given Rivaroxaban 3 mg/kg/day. In-group C (n = 5) Apixaban was administered per orally 10 mg/kg. At the end of the treatment on the 28th day, carotid artery specimens were excised and evaluated histologically.Results: Increased intima thickness was observed in the control group than the drug groups (P=0.019, P=0.007). It was found that there was no difference between groups in terms of lumen diameter, lumen area, tunica media area and tunica media thickness. There was difference between groups in terms of caspase 3 or TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining (p<0.05). Conclusion: Apixaban and Rivaroxaban may have protective efficacy against intimal hyperplasia after vascular surgical intervention.
- 25 October 2022
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 31 (3) , 148-156
Open AccessEffects of rivaroxaban and apixaban on intimal hyperplasia in rabbits
Aim: Intimal hyperplasia causes vascular occlusion and its optimal treatment is unknown. In this study, we evaluated the effectiveness of Apixaban and Rivaroxaban treatment for preventing intimal hyperplasia in rabbits. Material and Methods: The rabbits (n = 15) were randomly divided into three groups. Reanastomoses are applied to the carotid artery. All groups received 100 U/kg heparin sodium during the operation period. Group A (n = 5) as a control group had no medication. Group B (n = 5) was given Rivaroxaban 3 mg/kg/day. In-group C (n = 5) Apixaban was administered per orally 10 mg/kg. At the end of the treatment on the 28th day, carotid artery specimens were excised and evaluated histologically.Results: Increased intima thickness was observed in the control group than the drug groups (P=0.019, P=0.007). It was found that there was no difference between groups in terms of lumen diameter, lumen area, tunica media area and tunica media thickness. There was difference between groups in terms of caspase 3 or TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining (p<0.05). Conclusion: Apixaban and Rivaroxaban may have protective efficacy against intimal hyperplasia after vascular surgical intervention.
- Open Access
- 1 April 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (4) , 344
Reply to Letter to the Editor: “Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?”
- 1 April 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (4) , 344
Open AccessReply to Letter to the Editor: “Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?”
- Open Access
- 5 November 2021
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (11) , 821-828
Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway
Doxorubicin (DOX) is a well-known cardiotoxic agent, whereas sacubitril/valsartan (Sac/Val) is an effective treatment option in heart failure. In this study, we aimed to evaluate the effect of Sac/Val on DOX-induced cardiotoxicity in pretreatment mice model. A total of 24 mice were equally classified into 4 groups; control group, DOX (20 mg/kg; fifth day), Sac/Val (80 mg/kg), and Sac/Val+DOX (Sac/Val was given from day one of the study before doxorubicin administration). Electrocardiography parameters, including durations of QRS, ST, QT, PP segment, and QT/PQ index were measured. Total antioxidant status (TAS), total oxidant status (TOS), tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), IL-6, NT-proBNP concentrations, and Caspase 3 activity were evaluated. At the end of the 9-day study duration, QRS, ST, QT intervals, QT/PQ index and TAS, TOS, TNF-α, IL-1β, IL-6 levels were significantly higher in the DOX group than in the control group (p<0.001). Moreover, there were significant differences only in the PP interval when comparing the Sac/Val+DOX and control groups (p<0.001). QRS, ST, QT intervals, and QT/PQ index, TAS, TOS, TNF-α, IL-1β, IL-6 levels were significantly lower in the Sac/Val+ DOX group compared with the DOX group (p<0.001). Furthermore, NT-proBNP levels were lower in the Sac/Val+DOX group compared with the DOX group along with less Caspase 3 apoptosis. Sac/Val seems to be cardioprotective against DOX-induced cardiotoxicity in pretreatment mice model. These findings can be attributed to the antiarrhythmic, anti-inflammatory, antioxidant, and antiapoptotic effects of Sac/Val as shown in this study.
- 5 November 2021
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (11) , 821-828
Open AccessAngiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway
Doxorubicin (DOX) is a well-known cardiotoxic agent, whereas sacubitril/valsartan (Sac/Val) is an effective treatment option in heart failure. In this study, we aimed to evaluate the effect of Sac/Val on DOX-induced cardiotoxicity in pretreatment mice model. A total of 24 mice were equally classified into 4 groups; control group, DOX (20 mg/kg; fifth day), Sac/Val (80 mg/kg), and Sac/Val+DOX (Sac/Val was given from day one of the study before doxorubicin administration). Electrocardiography parameters, including durations of QRS, ST, QT, PP segment, and QT/PQ index were measured. Total antioxidant status (TAS), total oxidant status (TOS), tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), IL-6, NT-proBNP concentrations, and Caspase 3 activity were evaluated. At the end of the 9-day study duration, QRS, ST, QT intervals, QT/PQ index and TAS, TOS, TNF-α, IL-1β, IL-6 levels were significantly higher in the DOX group than in the control group (p<0.001). Moreover, there were significant differences only in the PP interval when comparing the Sac/Val+DOX and control groups (p<0.001). QRS, ST, QT intervals, and QT/PQ index, TAS, TOS, TNF-α, IL-1β, IL-6 levels were significantly lower in the Sac/Val+ DOX group compared with the DOX group (p<0.001). Furthermore, NT-proBNP levels were lower in the Sac/Val+DOX group compared with the DOX group along with less Caspase 3 apoptosis. Sac/Val seems to be cardioprotective against DOX-induced cardiotoxicity in pretreatment mice model. These findings can be attributed to the antiarrhythmic, anti-inflammatory, antioxidant, and antiapoptotic effects of Sac/Val as shown in this study.
- 3 August 2020
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 69 (3) , 425-433
Effect of bivalirudin on neointimal hyperplasia and endothelial proliferation in rabbit
Background The aim of this study was to investigate the effects of bivalirudin on endothelial cell proliferation and neointimal hyperplasia in a rabbit carotid artery model. Methods “New Zealand rabbits (n = 12)” weighing 2–3 kg were randomly divided into two groups. Arteriotomy was performed to the rabbit carotid artery and closed with continuous suture technique. Group B (n = 6) as a control group received 150 U/kg heparin sodium; however, group A (n = 6) was given 0.75 mg/kg bivalirudin i.v. bolus and infusion 1.75 mg/kg/hour (B01AE06-Bivalirudin 250 mg) during perioperation period. At the end of the 28th day, the carotid artery segment was excised and evaluated histologically. Results All histological and immune staining analyzes were performed by two blind researchers in the treatment of rabbits. In the control group rabbit carotid artery sections, tunica intima was observed to thicken. In the bivalirudin group, intimal hyperplasia was less observed compared to the control group. No significant difference was observed between groups in tunica media thickness. Lumen diameter and lumen area were found to be wider in the experimental group. P value was found to be less than 0.05. Conclusion Our study demonstrates that bivalirudin significantly affects and prevents neointimal hyperplasia and endothelial cell proliferation.
- 3 August 2020
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 69 (3) , 425-433
Effect of bivalirudin on neointimal hyperplasia and endothelial proliferation in rabbit
Background The aim of this study was to investigate the effects of bivalirudin on endothelial cell proliferation and neointimal hyperplasia in a rabbit carotid artery model. Methods “New Zealand rabbits (n = 12)” weighing 2–3 kg were randomly divided into two groups. Arteriotomy was performed to the rabbit carotid artery and closed with continuous suture technique. Group B (n = 6) as a control group received 150 U/kg heparin sodium; however, group A (n = 6) was given 0.75 mg/kg bivalirudin i.v. bolus and infusion 1.75 mg/kg/hour (B01AE06-Bivalirudin 250 mg) during perioperation period. At the end of the 28th day, the carotid artery segment was excised and evaluated histologically. Results All histological and immune staining analyzes were performed by two blind researchers in the treatment of rabbits. In the control group rabbit carotid artery sections, tunica intima was observed to thicken. In the bivalirudin group, intimal hyperplasia was less observed compared to the control group. No significant difference was observed between groups in tunica media thickness. Lumen diameter and lumen area were found to be wider in the experimental group. P value was found to be less than 0.05. Conclusion Our study demonstrates that bivalirudin significantly affects and prevents neointimal hyperplasia and endothelial cell proliferation.